Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 109 entries
Sorted by: Best Match Show Resources per page
Biological properties of extracellular vesicles and their physiological functions.

Journal of extracellular vesicles

Yáñez-Mó M, Siljander PR, Andreu Z, Zavec AB, Borràs FE, Buzas EI, Buzas K, Casal E, Cappello F, Carvalho J, Colás E, Cordeiro-da Silva A, Fais S, Falcon-Perez JM, Ghobrial IM, Giebel B, Gimona M, Graner M, Gursel I, Gursel M, Heegaard NH, Hendrix A, Kierulf P, Kokubun K, Kosanovic M, Kralj-Iglic V, Krämer-Albers EM, Laitinen S, Lässer C, Lener T, Ligeti E, Linē A, Lipps G, Llorente A, Lötvall J, Manček-Keber M, Marcilla A, Mittelbrunn M, Nazarenko I, Nolte-'t Hoen EN, Nyman TA, O'Driscoll L, Olivan M, Oliveira C, Pállinger É, Del Portillo HA, Reventós J, Rigau M, Rohde E, Sammar M, Sánchez-Madrid F, Santarém N, Schallmoser K, Ostenfeld MS, Stoorvogel W, Stukelj R, Van der Grein SG, Vasconcelos MH, Wauben MH, De Wever O.
PMID: 25979354
J Extracell Vesicles. 2015 May 14;4:27066. doi: 10.3402/jev.v4.27066. eCollection 2015.

In the past decade, extracellular vesicles (EVs) have been recognized as potent vehicles of intercellular communication, both in prokaryotes and eukaryotes. This is due to their capacity to transfer proteins, lipids and nucleic acids, thereby influencing various physiological and...

Cite
Yáñez-Mó M, Siljander PR, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015;4:27066doi: 10.3402/jev.v4.27066.
Yáñez-Mó, M., Siljander, P. R., Andreu, Z., Zavec, A. B., Borràs, F. E., Buzas, E. I., Buzas, K., Casal, E., Cappello, F., Carvalho, J., Colás, E., Cordeiro-da Silva, A., Fais, S., Falcon-Perez, J. M., Ghobrial, I. M., Giebel, B., Gimona, M., Graner, M., Gursel, I., Gursel, M., Heegaard, N. H., Hendrix, A., Kierulf, P., Kokubun, K., Kosanovic, M., Kralj-Iglic, V., Krämer-Albers, E. M., Laitinen, S., Lässer, C., Lener, T., Ligeti, E., Linē, A., Lipps, G., Llorente, A., Lötvall, J., Manček-Keber, M., Marcilla, A., Mittelbrunn, M., Nazarenko, I., Nolte-'t Hoen, E. N., Nyman, T. A., O'Driscoll, L., Olivan, M., Oliveira, C., Pállinger, �. �., Del Portillo, H. A., Reventós, J., Rigau, M., Rohde, E., Sammar, M., Sánchez-Madrid, F., Santarém, N., Schallmoser, K., Ostenfeld, M. S., Stoorvogel, W., Stukelj, R., Van der Grein, S. G., Vasconcelos, M. H., Wauben, M. H., & De Wever, O. (2015). Biological properties of extracellular vesicles and their physiological functions. Journal of extracellular vesicles, 427066. https://doi.org/10.3402/jev.v4.27066
Yáñez-Mó, María, et al. "Biological properties of extracellular vesicles and their physiological functions." Journal of extracellular vesicles vol. 4 (2015): 27066. doi: https://doi.org/10.3402/jev.v4.27066
Yáñez-Mó M, Siljander PR, Andreu Z, Zavec AB, Borràs FE, Buzas EI, Buzas K, Casal E, Cappello F, Carvalho J, Colás E, Cordeiro-da Silva A, Fais S, Falcon-Perez JM, Ghobrial IM, Giebel B, Gimona M, Graner M, Gursel I, Gursel M, Heegaard NH, Hendrix A, Kierulf P, Kokubun K, Kosanovic M, Kralj-Iglic V, Krämer-Albers EM, Laitinen S, Lässer C, Lener T, Ligeti E, Linē A, Lipps G, Llorente A, Lötvall J, Manček-Keber M, Marcilla A, Mittelbrunn M, Nazarenko I, Nolte-'t Hoen EN, Nyman TA, O'Driscoll L, Olivan M, Oliveira C, Pállinger É, Del Portillo HA, Reventós J, Rigau M, Rohde E, Sammar M, Sánchez-Madrid F, Santarém N, Schallmoser K, Ostenfeld MS, Stoorvogel W, Stukelj R, Van der Grein SG, Vasconcelos MH, Wauben MH, De Wever O. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015 May 14;4:27066. doi: 10.3402/jev.v4.27066. eCollection 2015. PMID: 25979354; PMCID: PMC4433489.
Copy Download .nbib Format: NLM
Inflammatory Conditions Dictate the Effect of Mesenchymal Stem or Stromal Cells on B Cell Function.

Frontiers in immunology

Luk F, Carreras-Planella L, Korevaar SS, de Witte SFH, Borràs FE, Betjes MGH, Baan CC, Hoogduijn MJ, Franquesa M.
PMID: 28894451
Front Immunol. 2017 Aug 28;8:1042. doi: 10.3389/fimmu.2017.01042. eCollection 2017.

The immunomodulatory capacity of mesenchymal stem or stromal cells (MSC) makes them a promising tool for treatment of immune disease and organ transplantation. The effects of MSC on B cells are characterized by an abrogation of plasmablast formation and...

Cite
Luk F, Carreras-Planella L, Korevaar SS, et al. Inflammatory Conditions Dictate the Effect of Mesenchymal Stem or Stromal Cells on B Cell Function. Front Immunol. 2017;8:1042doi: 10.3389/fimmu.2017.01042.
Luk, F., Carreras-Planella, L., Korevaar, S. S., de Witte, S. F. H., Borràs, F. E., Betjes, M. G. H., Baan, C. C., Hoogduijn, M. J., & Franquesa, M. (2017). Inflammatory Conditions Dictate the Effect of Mesenchymal Stem or Stromal Cells on B Cell Function. Frontiers in immunology, 81042. https://doi.org/10.3389/fimmu.2017.01042
Luk, Franka, et al. "Inflammatory Conditions Dictate the Effect of Mesenchymal Stem or Stromal Cells on B Cell Function." Frontiers in immunology vol. 8 (2017): 1042. doi: https://doi.org/10.3389/fimmu.2017.01042
Luk F, Carreras-Planella L, Korevaar SS, de Witte SFH, Borràs FE, Betjes MGH, Baan CC, Hoogduijn MJ, Franquesa M. Inflammatory Conditions Dictate the Effect of Mesenchymal Stem or Stromal Cells on B Cell Function. Front Immunol. 2017 Aug 28;8:1042. doi: 10.3389/fimmu.2017.01042. eCollection 2017. PMID: 28894451; PMCID: PMC5581385.
Copy Download .nbib Format: NLM
Tolerance in organ transplantation: from conventional immunosuppression to extracellular vesicles.

Frontiers in immunology

Monguió-Tortajada M, Lauzurica-Valdemoros R, Borràs FE.
PMID: 25278936
Front Immunol. 2014 Sep 17;5:416. doi: 10.3389/fimmu.2014.00416. eCollection 2014.

Organ transplantation is often the unique solution for organ failure. However, rejection is still an unsolved problem. Although acute rejection is well controlled, the chronic use of immunosuppressive drugs for allograft acceptance causes numerous side effects in the recipient...

Cite
Monguió-Tortajada M, Lauzurica-Valdemoros R, Borràs FE. Tolerance in organ transplantation: from conventional immunosuppression to extracellular vesicles. Front Immunol. 2014;5:416doi: 10.3389/fimmu.2014.00416.
Monguió-Tortajada, M., Lauzurica-Valdemoros, R., & Borràs, F. E. (2014). Tolerance in organ transplantation: from conventional immunosuppression to extracellular vesicles. Frontiers in immunology, 5416. https://doi.org/10.3389/fimmu.2014.00416
Monguió-Tortajada, Marta, et al. "Tolerance in organ transplantation: from conventional immunosuppression to extracellular vesicles." Frontiers in immunology vol. 5 (2014): 416. doi: https://doi.org/10.3389/fimmu.2014.00416
Monguió-Tortajada M, Lauzurica-Valdemoros R, Borràs FE. Tolerance in organ transplantation: from conventional immunosuppression to extracellular vesicles. Front Immunol. 2014 Sep 17;5:416. doi: 10.3389/fimmu.2014.00416. eCollection 2014. PMID: 25278936; PMCID: PMC4166341.
Copy Download .nbib Format: NLM
Antimicrobial activity of poly(3,4-ethylenedioxythiophene) n-doped with a pyridinium-containing polyelectrolyte.

Soft matter

Sánchez-Jiménez M, Estrany F, Borràs N, Maiti B, Díaz Díaz D, Del Valle LJ, Alemán C.
PMID: 31502620
Soft Matter. 2019 Oct 14;15(38):7695-7703. doi: 10.1039/c9sm01491h. Epub 2019 Sep 10.

In spite of p-doped conducting polymers having been widely studied in the last decades and many applications having been developed, studies based on n-doped conducting polymers are extremely scarce. This fact is even more evident when it comes to...

Cite
Sánchez-Jiménez M, Estrany F, Borràs N, et al. Antimicrobial activity of poly(3,4-ethylenedioxythiophene) n-doped with a pyridinium-containing polyelectrolyte. Soft Matter. 2019;15(38):7695-7703doi: 10.1039/c9sm01491h.
Sánchez-Jiménez, M., Estrany, F., Borràs, N., Maiti, B., Díaz Díaz, D., Del Valle, L. J., & Alemán, C. (2019). Antimicrobial activity of poly(3,4-ethylenedioxythiophene) n-doped with a pyridinium-containing polyelectrolyte. Soft matter, 15(38), 7695-7703. https://doi.org/10.1039/c9sm01491h
Sánchez-Jiménez, Margarita, et al. "Antimicrobial activity of poly(3,4-ethylenedioxythiophene) n-doped with a pyridinium-containing polyelectrolyte." Soft matter vol. 15,38 (2019): 7695-7703. doi: https://doi.org/10.1039/c9sm01491h
Sánchez-Jiménez M, Estrany F, Borràs N, Maiti B, Díaz Díaz D, Del Valle LJ, Alemán C. Antimicrobial activity of poly(3,4-ethylenedioxythiophene) n-doped with a pyridinium-containing polyelectrolyte. Soft Matter. 2019 Oct 14;15(38):7695-7703. doi: 10.1039/c9sm01491h. Epub 2019 Sep 10. PMID: 31502620.
Copy Download .nbib Format: NLM
Physiological Responses to Swimming-Induced Exercise in the Adult Zebrafish Regenerating Heart.

Frontiers in physiology

Rovira M, Borràs DM, Marques IJ, Puig C, Planas JV.
PMID: 30327615
Front Physiol. 2018 Oct 01;9:1362. doi: 10.3389/fphys.2018.01362. eCollection 2018.

Exercise promotes a set of physiological responses known to provide long-term health benefits and it can play an important role in cardioprotection. In the present study, we examined cardiac responses to exercise training in the adult zebrafish and in...

Cite
Rovira M, Borràs DM, Marques IJ, et al. Physiological Responses to Swimming-Induced Exercise in the Adult Zebrafish Regenerating Heart. Front Physiol. 2018;9:1362doi: 10.3389/fphys.2018.01362.
Rovira, M., Borràs, D. M., Marques, I. J., Puig, C., & Planas, J. V. (2018). Physiological Responses to Swimming-Induced Exercise in the Adult Zebrafish Regenerating Heart. Frontiers in physiology, 91362. https://doi.org/10.3389/fphys.2018.01362
Rovira, Mireia, et al. "Physiological Responses to Swimming-Induced Exercise in the Adult Zebrafish Regenerating Heart." Frontiers in physiology vol. 9 (2018): 1362. doi: https://doi.org/10.3389/fphys.2018.01362
Rovira M, Borràs DM, Marques IJ, Puig C, Planas JV. Physiological Responses to Swimming-Induced Exercise in the Adult Zebrafish Regenerating Heart. Front Physiol. 2018 Oct 01;9:1362. doi: 10.3389/fphys.2018.01362. eCollection 2018. PMID: 30327615; PMCID: PMC6174316.
Copy Download .nbib Format: NLM
Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis.

Cancer prevention research (Philadelphia, Pa.)

Bowen CM, Walter L, Borras E, Wu W, Ozcan Z, Chang K, Bommi PV, Taggart MW, Thirumurthi S, Lynch PM, Reyes-Uribe L, Scheet PA, Sinha KM, Vilar E.
PMID: 34266857
Cancer Prev Res (Phila). 2021 Sep;14(9):851-862. doi: 10.1158/1940-6207.CAPR-20-0496. Epub 2021 Jul 15.

Familial adenomatous polyposis (FAP) is a hereditary colorectal cancer syndrome, which results in the development of hundreds of adenomatous polyps carpeting the gastrointestinal tract. NSAIDs have reduced polyp burden in patients with FAP and synthetic rexinoids have demonstrated the...

Cite
Bowen CM, Walter L, Borras E, et al. Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis. Cancer Prev Res (Phila). 2021;14(9):851-862doi: 10.1158/1940-6207.CAPR-20-0496.
Bowen, C. M., Walter, L., Borras, E., Wu, W., Ozcan, Z., Chang, K., Bommi, P. V., Taggart, M. W., Thirumurthi, S., Lynch, P. M., Reyes-Uribe, L., Scheet, P. A., Sinha, K. M., & Vilar, E. (2021). Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis. Cancer prevention research (Philadelphia, Pa.), 14(9), 851-862. https://doi.org/10.1158/1940-6207.CAPR-20-0496
Bowen, Charles M, et al. "Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis." Cancer prevention research (Philadelphia, Pa.) vol. 14,9 (2021): 851-862. doi: https://doi.org/10.1158/1940-6207.CAPR-20-0496
Bowen CM, Walter L, Borras E, Wu W, Ozcan Z, Chang K, Bommi PV, Taggart MW, Thirumurthi S, Lynch PM, Reyes-Uribe L, Scheet PA, Sinha KM, Vilar E. Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis. Cancer Prev Res (Phila). 2021 Sep;14(9):851-862. doi: 10.1158/1940-6207.CAPR-20-0496. Epub 2021 Jul 15. PMID: 34266857; PMCID: PMC8416926.
Copy Download .nbib Format: NLM
Trends in lung cancer incidence by age, sex and histology from 2012 to 2025 in Catalonia (Spain).

Scientific reports

Guarga L, Ameijide A, Marcos-Gragera R, Carulla M, Delgadillo J, Borràs JM, Galceran J.
PMID: 34857781
Sci Rep. 2021 Dec 02;11(1):23274. doi: 10.1038/s41598-021-02582-8.

Lung cancer remains one the most common cancers in Europe and ranks first in terms of cancer mortality in both sexes. Incidence rates vary by region and depend above all on the prevalence of tobacco consumption. In this study...

Cite
Guarga L, Ameijide A, Marcos-Gragera R, et al. Trends in lung cancer incidence by age, sex and histology from 2012 to 2025 in Catalonia (Spain). Sci Rep. 2021;11(1):23274doi: 10.1038/s41598-021-02582-8.
Guarga, L., Ameijide, A., Marcos-Gragera, R., Carulla, M., Delgadillo, J., Borràs, J. M., & Galceran, J. (2021). Trends in lung cancer incidence by age, sex and histology from 2012 to 2025 in Catalonia (Spain). Scientific reports, 11(1), 23274. https://doi.org/10.1038/s41598-021-02582-8
Guarga, Laura, et al. "Trends in lung cancer incidence by age, sex and histology from 2012 to 2025 in Catalonia (Spain)." Scientific reports vol. 11,1 (2021): 23274. doi: https://doi.org/10.1038/s41598-021-02582-8
Guarga L, Ameijide A, Marcos-Gragera R, Carulla M, Delgadillo J, Borràs JM, Galceran J. Trends in lung cancer incidence by age, sex and histology from 2012 to 2025 in Catalonia (Spain). Sci Rep. 2021 Dec 02;11(1):23274. doi: 10.1038/s41598-021-02582-8. PMID: 34857781; PMCID: PMC8639747.
Copy Download .nbib Format: NLM
Inactivation of SARS-CoV-2 in clinical exhaled breath condensate samples for metabolomic analysis.

Journal of breath research

Hu S, McCartney MM, Arredondo J, Sankaran-Walters S, Borras E, Harper RW, Schivo M, Davis CE, Kenyon NJ, Dandekar S.
PMID: 34852327
J Breath Res. 2021 Dec 20;16(1). doi: 10.1088/1752-7163/ac3f24.

Exhaled breath condensate (EBC) is routinely collected and analyzed in breath research. Because it contains aerosol droplets, EBC samples from SARS-CoV-2 infected individuals harbor the virus and pose the threat of infectious exposure. We report for the first time...

Cite
Hu S, McCartney MM, Arredondo J, et al. Inactivation of SARS-CoV-2 in clinical exhaled breath condensate samples for metabolomic analysis. J Breath Res. 2021;16(1)doi: 10.1088/1752-7163/ac3f24.
Hu, S., McCartney, M. M., Arredondo, J., Sankaran-Walters, S., Borras, E., Harper, R. W., Schivo, M., Davis, C. E., Kenyon, N. J., & Dandekar, S. (2021). Inactivation of SARS-CoV-2 in clinical exhaled breath condensate samples for metabolomic analysis. Journal of breath research, 16(1), . https://doi.org/10.1088/1752-7163/ac3f24
Hu, Shuang, et al. "Inactivation of SARS-CoV-2 in clinical exhaled breath condensate samples for metabolomic analysis." Journal of breath research vol. 16,1 (2021). doi: https://doi.org/10.1088/1752-7163/ac3f24
Hu S, McCartney MM, Arredondo J, Sankaran-Walters S, Borras E, Harper RW, Schivo M, Davis CE, Kenyon NJ, Dandekar S. Inactivation of SARS-CoV-2 in clinical exhaled breath condensate samples for metabolomic analysis. J Breath Res. 2021 Dec 20;16(1). doi: 10.1088/1752-7163/ac3f24. PMID: 34852327.
Copy Download .nbib Format: NLM
Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review.

BMC public health

Palacio-Vieira J, Reyes-Urueña JM, Imaz A, Bruguera A, Force L, Llaveria AO, Llibre JM, Vilaró I, Borràs FH, Falcó V, Riera M, Domingo P, de Lazzari E, Miró JM, Casabona J.
PMID: 34454444
BMC Public Health. 2021 Aug 28;21(1):1596. doi: 10.1186/s12889-021-11613-y.

BACKGROUND: Despite remarkable achievements in antiretroviral therapy (ART), losses to follow-up (LTFU) might prevent the long-term success of HIV treatment and might delay the achievement of the 90-90-90 objectives. This scoping review is aimed at the description and analysis...

Cite
Palacio-Vieira J, Reyes-Urueña JM, Imaz A, et al. Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review. BMC Public Health. 2021;21(1):1596doi: 10.1186/s12889-021-11613-y.
Palacio-Vieira, J., Reyes-Urueña, J. M., Imaz, A., Bruguera, A., Force, L., Llaveria, A. O., Llibre, J. M., Vilaró, I., Borràs, F. H., Falcó, V., Riera, M., Domingo, P., de Lazzari, E., Miró, J. M., Casabona, J. (2021). Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review. BMC public health, 21(1), 1596. https://doi.org/10.1186/s12889-021-11613-y
Palacio-Vieira, Jorge, et al. "Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review." BMC public health vol. 21,1 (2021): 1596. doi: https://doi.org/10.1186/s12889-021-11613-y
Palacio-Vieira J, Reyes-Urueña JM, Imaz A, Bruguera A, Force L, Llaveria AO, Llibre JM, Vilaró I, Borràs FH, Falcó V, Riera M, Domingo P, de Lazzari E, Miró JM, Casabona J. Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review. BMC Public Health. 2021 Aug 28;21(1):1596. doi: 10.1186/s12889-021-11613-y. PMID: 34454444; PMCID: PMC8403456.
Copy Download .nbib Format: NLM
Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study).

BMJ open

Colomer-Carbonell A, Sanabria-Mazo JP, Hernández-Negrín H, Borràs X, Suso-Ribera C, García-Palacios A, Muchart J, Munuera J, D'Amico F, Maes M, Younger JW, Feliu-Soler A, Rozadilla-Sacanell A, Luciano JV.
PMID: 34992118
BMJ Open. 2022 Jan 06;12(1):e055351. doi: 10.1136/bmjopen-2021-055351.

INTRODUCTION: There is evidence that low-dose naltrexone (LDN;

Cite
Colomer-Carbonell A, Sanabria-Mazo JP, Hernández-Negrín H, et al. Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study). BMJ Open. 2022;12(1):e055351doi: 10.1136/bmjopen-2021-055351.
Colomer-Carbonell, A., Sanabria-Mazo, J. P., Hernández-Negrín, H., Borràs, X., Suso-Ribera, C., García-Palacios, A., Muchart, J., Munuera, J., D'Amico, F., Maes, M., Younger, J. W., Feliu-Soler, A., Rozadilla-Sacanell, A., & Luciano, J. V. (2022). Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study). BMJ open, 12(1), e055351. https://doi.org/10.1136/bmjopen-2021-055351
Colomer-Carbonell, Ariadna, et al. "Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study)." BMJ open vol. 12,1 (2022): e055351. doi: https://doi.org/10.1136/bmjopen-2021-055351
Colomer-Carbonell A, Sanabria-Mazo JP, Hernández-Negrín H, Borràs X, Suso-Ribera C, García-Palacios A, Muchart J, Munuera J, D'Amico F, Maes M, Younger JW, Feliu-Soler A, Rozadilla-Sacanell A, Luciano JV. Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study). BMJ Open. 2022 Jan 06;12(1):e055351. doi: 10.1136/bmjopen-2021-055351. PMID: 34992118.
Copy Download .nbib Format: NLM
Salmerón et al Respond to "Predicting incidence rates of rare cancers: adding epidemiologic and spatial contexts".

American journal of epidemiology

Salmerón D, Botta L, Martínez JM, Trama A, Gatta G, Borràs JM, Capocaccia R, Clèries R, Rare Cancers-RARECAREnet Working Group ATINO.
PMID: 34874996
Am J Epidemiol. 2021 Dec 07; doi: 10.1093/aje/kwab286. Epub 2021 Dec 07.

No abstract available.

Cite
Salmerón D, Botta L, Martínez JM, et al. Salmerón et al Respond to "Predicting incidence rates of rare cancers: adding epidemiologic and spatial contexts". Am J Epidemiol. 2021;doi: 10.1093/aje/kwab286.
Salmerón, D., Botta, L., Martínez, J. M., Trama, A., Gatta, G., Borràs, J. M., Capocaccia, R., Clèries, R., & Rare Cancers-RARECAREnet Working Group, A. T. I. N. O. (2021). Salmerón et al Respond to "Predicting incidence rates of rare cancers: adding epidemiologic and spatial contexts". American journal of epidemiology, . https://doi.org/10.1093/aje/kwab286
Salmerón, Diego, et al. "Salmerón et al Respond to "Predicting incidence rates of rare cancers: adding epidemiologic and spatial contexts"." American journal of epidemiology vol. (2021). doi: https://doi.org/10.1093/aje/kwab286
Salmerón D, Botta L, Martínez JM, Trama A, Gatta G, Borràs JM, Capocaccia R, Clèries R, Rare Cancers-RARECAREnet Working Group ATINO. Salmerón et al Respond to "Predicting incidence rates of rare cancers: adding epidemiologic and spatial contexts". Am J Epidemiol. 2021 Dec 07; doi: 10.1093/aje/kwab286. Epub 2021 Dec 07. PMID: 34874996.
Copy Download .nbib Format: NLM
Estimating Country-Specific Incidence Rates of Rare Cancers: Comparative Performance Analysis of Modelling Approaches Using European Cancer Registry Data.

American journal of epidemiology

Salmerón D, Botta L, Martínez JM, Trama A, Gatta G, Borràs JM, Capocaccia R, Clèries R, Rare Cancers-RARECAREnet Working Group ATINO.
PMID: 34718388
Am J Epidemiol. 2021 Oct 29; doi: 10.1093/aje/kwab262. Epub 2021 Oct 29.

Estimating incidence for rare cancers (RC) is challenging for exceptionally rare entities and in small populations. In a previous study, the RARECAREnet project provided Bayesian estimates of the expected number of RCs and their 95% credible intervals for 27...

Cite
Salmerón D, Botta L, Martínez JM, et al. Estimating Country-Specific Incidence Rates of Rare Cancers: Comparative Performance Analysis of Modelling Approaches Using European Cancer Registry Data. Am J Epidemiol. 2021;doi: 10.1093/aje/kwab262.
Salmerón, D., Botta, L., Martínez, J. M., Trama, A., Gatta, G., Borràs, J. M., Capocaccia, R., Clèries, R., & Rare Cancers-RARECAREnet Working Group, A. T. I. N. O. (2021). Estimating Country-Specific Incidence Rates of Rare Cancers: Comparative Performance Analysis of Modelling Approaches Using European Cancer Registry Data. American journal of epidemiology, . https://doi.org/10.1093/aje/kwab262
Salmerón, Diego, et al. "Estimating Country-Specific Incidence Rates of Rare Cancers: Comparative Performance Analysis of Modelling Approaches Using European Cancer Registry Data." American journal of epidemiology vol. (2021). doi: https://doi.org/10.1093/aje/kwab262
Salmerón D, Botta L, Martínez JM, Trama A, Gatta G, Borràs JM, Capocaccia R, Clèries R, Rare Cancers-RARECAREnet Working Group ATINO. Estimating Country-Specific Incidence Rates of Rare Cancers: Comparative Performance Analysis of Modelling Approaches Using European Cancer Registry Data. Am J Epidemiol. 2021 Oct 29; doi: 10.1093/aje/kwab262. Epub 2021 Oct 29. PMID: 34718388.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 109 entries